title: Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival.
abstract: BACKGROUND
  Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) tumor expression is an emerging prognostic, diagnostic, and therapeutic target in early epithelial ovarian cancer (EOC). The significance of tumor overexpression of LPAAT-beta was investigated in a large number of advanced- and early-stage EOC patients.
  
  
  METHODS
  LPAAT-beta expression was analyzed by immunohistochemistry (IHC) in 158 ovarian tumors, including 68 advanced and 90 low-stage tumors, representing all grades and histologies (including 33 borderline tumors). In advanced-stage patients, tissue from multiple sites was evaluated to assess differential expression of LPAAT-beta in local tumor and distant metastases.
  
  
  RESULTS
  LPAAT-beta was overexpressed in 90 (57%) of all 158 ovarian tumors. Forty-nine (72%) of 68 advanced tumors overexpressed LPAAT-beta. LPAAT-beta was associated with the presence of carcinoma versus borderline histology (67% vs. 18%, P < .0001), high histologic grade [according to the Silverberg Grading Scheme] (Grade 1, 25%; Grade 2, 21%; and Grade 3, 54%; P < .0001), and with papillary-serous histology. In an analysis of the 125 carcinoma patients, LPAAT-beta increased with but was not significantly associated with advanced clinical stage (P = .1431). LPAAT-beta expression was associated with shortened progression-free survival (PFS) (5-year PFS, 32% for LPAAT-beta-positive vs. 60% for LPAAT-beta-negative; P = .0318) and decreased overall survival (OS) (5-year OS, 54% for LPAAT-beta-positive vs. 74% for LPAAT-beta-negative; P = .0173).
  
  
  CONCLUSIONS
  LPAAT-beta is highly expressed in advanced ovarian tumors and is associated with aggressive histology and decreased PFS and OS. LPAAT-beta is an intriguing prognostic tool for the identification of high-risk EOC and a potential target for directed therapy that warrants further study.
authors.affiliation: Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
authors.forename: Catherine S M
authors.initials: CS
authors.lastname: Diefenbach
authors.forename: Robert A
authors.initials: RA
authors.lastname: Soslow
authors.forename: Alexia
authors.initials: A
authors.lastname: Iasonos
authors.forename: Irina
authors.initials: I
authors.lastname: Linkov
authors.forename: Cyrus
authors.initials: C
authors.lastname: Hedvat
authors.forename: Lynn
authors.initials: L
authors.lastname: Bonham
authors.forename: Jack
authors.initials: J
authors.lastname: Singer
authors.forename: Richard R
authors.initials: RR
authors.lastname: Barakat
authors.forename: Carol
authors.initials: C
authors.lastname: Aghajanian
authors.forename: Jakob
authors.initials: J
authors.lastname: Dupont
mesh_terms: D000217:Acyltransferases / Q000032:analysis*; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology*; D010053:Ovary / Q000201:enzymology* / Q000473:pathology*; D016019:Survival Analysis
chemical_list: D000217:Acyltransferases; C018764:2-acylglycerophosphate acyltransferase